CSIMarket Company Name, Ticker, Customers, else..
 
Atyr Pharma Inc   (NASDAQ: ATYR)
 
Price: $0.4808 $-0.02 -3.260%
Day's High: $0.5099999904632568 Week Perf: 0.8 %
Day's Low: $ 0.48 30 Day Perf: -5.91 %
Volume (M): 631,855 52 Wk High: $ 6.50
Volume (M$): $ 0 52 Wk Avg: $0.79
Open: $0.51 52 Wk Low: $0.40



 Market Capitalization (Millions $) 47
 Shares Outstanding (Millions) 98
 Employees 58
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -61
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Business Description


aTyr Pharma, Inc. and its subsidiary, Pangu BioPharma Limited, engage in the research and development of biopharmaceutical products. The company conducts clinical trials and manages intellectual property, including trademarks, as part of its efforts to develop and commercialize these products.


   Company Address: 10240 Sorrento Valley Road San Diego 92121 CA
   Company Phone Number: 731-8389   Stock Exchange / Ticker: NASDAQ ATYR


Customers Net Income fell by ATYR's Customers Net Profit Margin fell to

-44.29 %
6.82 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A   -4.37%    
DHR   -3.9%    
HON   -2.48%    
RVTY   -1.24%    
TMO   -2.28%    
• View Complete Report
   



Announcement

Shadows and Opportunities The Legal Landscape of aTyr Pharma and Implications for Investors

Published Mon, Oct 20 2025 9:21 AM UTC

In recent weeks, the financial theatre surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) has stirred significant concern among its investors, culminating in a class action lawsuit heralded by Pomerantz LLP. As the fiscal tides of the biotechnology sector swell with uncertainty, it becomes imperative for investors who have sustained losses in their investment in aTyr to comprehend...
Management Changes

aTyr Pharma Strengthens Position in Anti-Fibrotic Research and Oncology with Key Appointments and Promising Therapeutics for Fibrotic Diseases and GBM

Published Wed, Mar 26 2025 12:02 PM UTC

In recent months, aTyr Pharma has made significant strides in the development of innovative therapies for complex medical conditions, highlighting its commitment to enhancing treatment outcomes for patients. Central to this momentum is the appointment of Dalia R. Rayes as the Head of Commercial for the Global Efzofitimod Franchise, reflecting a strategic focus on acceleratin...
Clinical Study

Advancements in Anti-Fibrotic Research and Oncology aTyr Pharmas Groundbreaking Studies Highlight Potential Treatmen...

Published Tue, Dec 31 2024 11:06 AM UTC

As our understanding of fibrotic diseases and complex tumors such as glioblastoma multiforme (GBM) progresses, novel therapeutic approaches are emerging to offer hope for patients afflicted by these challenging conditions. aTyr Pharma, a biopharmaceutical company dedicated to developing innovative therapies, has recently made significant strides in the field of anti-fibrotic...
Clinical Study

“Navigating Progress aTyr Pharma’s Promising Advances in Pulmonary Sarcoidosis Treatment”

Published Mon, Dec 30 2024 8:39 AM UTC

Recent developments in the biopharmaceutical sector are underscoring the potential of innovative therapies for chronic conditions. Among these, aTyr Pharma Inc. is making notable strides with its investigational therapy, Efzofitimod, currently under evaluation in the Phase 3 EFZO-FIT study for pulmonary sarcoidosis. Amidst the backdrop of fluctuating market conditions, the ...
Clinical Study

Targeting Neuropilin-2 aTyr Pharmas Innovative Approach to Glioblastoma Multiforme

Published Tue, Jul 30 2024 12:00 PM UTC

Glioblastoma multiforme (GBM) represents one of the most aggressive forms of brain cancer, characterized by rapid progression and poor prognosis despite aggressive treatment options. The standard interventions, including surgical resection, radiotherapy, and chemotherapy, frequently result in limited survival benefits, which highlights the urgent need for innovative therapeu...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 248.17
Price to Sales (Expected) -
Price to Book 0.97
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.04
Working Capital Ratio 5.12
Leverage Ratio (MRQ) 0.43
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.63 $
Revenues (TTM) 0 $
Cash Flow (TTM) -
Cash 0.59 $
Book Value 0.5 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,048,483
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.